Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Board Meeting Outcome for Unaudited Financial Results (Standalone And Consolidated) For The Second Quarter And Half Year Ended 30Th September, 2023

Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Board at its meeting held today has approved the unaudited financial results for the Second Quarter and Half Year ended 30th September, 2023. The said Board Meeting commenced at 02:00 p.m. and ended at 06:40 p.m. The copy of the said results and Limited Review Report of Auditors is enclosed herewith. These are also being made available on the website of the Company at www.glenmarkpharma.com.
10-11-2023

Glenmark Pharmaceuticals Share Price Live blog for 10 Nov 2023

Glenmark Pharmaceuticals stock price went down today, 10 Nov 2023, by -0.34 %. The stock closed at 785.7 per share. The stock is currently trading at 783.05 per share. Investors should monitor Glenmark Pharmaceuticals stock price closely in the coming days and weeks to see how it reacts to the news.
10-11-2023

Glenmark Pharmaceuticals Share Price Live blog for 08 Nov 2023

Glenmark Pharmaceuticals stock price went up today, 08 Nov 2023, by 2.3 %. The stock closed at 759.2 per share. The stock is currently trading at 776.65 per share. Investors should monitor Glenmark Pharmaceuticals stock price closely in the coming days and weeks to see how it reacts to the news.
08-11-2023
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Shareholder Meeting / Postal Ballot-Outcome of Postal Ballot

Voting result as required under Regulation 44(3) of SEBI Listing Regulations and Scrutinizers Report is enclosed.
07-11-2023
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Glenmark Pharmaceuticals receives ANDA approval for Fluphenazine Hydrochloride Tablets USP, 1 mg, 2.5 mg, 5 mg, and 10 mg
07-11-2023
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Enclosed please find herewith the details of Earnings Call slated for Wednesday, November 15, 2023 at 8:30 a.m. - 9:30 a.m. (IST), for your information and record. Please note that the recording of the call will be available on our website within 24 hours of the call.
06-11-2023
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Closure of Trading Window

Intimation for closure of trading window
31-10-2023
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Board Meeting Intimation for Considering And Approving The Unaudited Financial Results Of The Company For The Second Quarter And Half Year Ended September 30, 2023

GLENMARK PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/11/2023 ,inter alia, to consider and approve the Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2023.
31-10-2023
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Glenmark Pharma is first to launch a Triple-drug FDC of Teneligliptin + Dapagliflozin + Metformin in India for Type 2 Diabetes in Adults with Co-morbidities
18-10-2023
Bigul

Glenmark Pharmaceuticals secures FDA approval, shares up

Glenmark's share up by 1.24 per cent to 807.35 at 11.17 am on the BSE
17-10-2023
Next Page
Close

Let's Open Free Demat Account